Analysis of metal complex with synchrotron spectroscopy

Purpose and goal

Deficiencies of nutrients is a major cause of health and economic harm. Renapharma is a pharmaceutical company offering nutrient supplements. The project, a collaboration between RISE and the project need owner, Renapharma, focuses on the synthesis of innovative compounds and the elucidation of their crystalline structure by single crystal X-ray diffraction (scXRD). The high intensity and high energy X-rays available at a synchrotron facility will allow us to determine the structure of very small crystals.

Expected effects and result

We plan to create a robust synthetic method for the synthesis of the complexes of interest, and we will use synchrotron light-based technology to elucidate the structure of the new complexes. We expect that the crystalline material used for synchrotron experiments and structure elucidation will subsequently be used by Renapharma as a reference material for further pharmaceutical development of a complex for future oral drug therapy.

Planned approach and implementation

The project consists of two phases. The first phase consists of the generation of different materials with varying components and synthetic methods. The materials will be analyzed with established analytical methods such as NMR, LC-MS, FTIR, DSC, XRPD and elemental analysis. The crystalline materials will be analyzed at a synchrotron by single crystal X-ray diffraction which will elucidate the nature of the materials. Based on the results, a reference material will be generated for future commercial manufacturing of the final product.